other_material
confidence high
sentiment positive
materiality 0.70
BioCardia CardiAMP trial roll-in cohort shows +80 sec exercise tolerance, 82% fewer angina episodes at 6 months
BioCardia, Inc.
- Open-label roll-in cohort (N not given) met primary endpoint; no treatment-emergent major adverse cardiac events.
- Average exercise tolerance improved by 80 seconds at six-month follow-up vs. pre-treatment.
- Angina episodes reduced by an average of 82% at the six-month primary endpoint.
- 60% of patients showed substantial improvement in both exercise tolerance and angina reduction.
- Results compare favorably to FDA-approved therapies Ranolazine and EECP; data to be submitted for peer review.
item 7.01item 9.01